Codon

DECEMBER 12, 2024

Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine. DNA and RNA molecules are also built from exclusively right-handed nucleic acids.

RNA 99

RNA DNA Vaccine Virus 99

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Additionally, Atea is planning to study in a Phase 3 clinical trial the use of AT-527 in the post-exposure prophylaxis setting. About Atea Pharmaceuticals.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Medical Schools Virus Science 137

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. Of those two dozen programs, 13 are now in clinical trials. 18, 2020 ). The company is unlikely to run short of research funding this year.

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

Codon

SEPTEMBER 29, 2024

But, regardless of which was first, they all operated with the same core data as their mechanism for understanding life: messenger RNA ( mRNA ). The average pass rate of phase I trials went up by 5 percent. There was scFormer in 2022, scGPT in 2023, and plenty of others. A flurry of new, promising therapeutic targets arose.

Engineering 131

Engineering Virus DNA Therapies 131

The Pharma Data

DECEMBER 3, 2020

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. The Phase 1 clinical trial was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccine 52

Vaccine Immune Response Virus RNA 52

PLOS: DNA Science

JULY 27, 2023

The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus. The fear is that a variant of the deadly virus might emerge that infects people, and, worst-case-scenario, passes from person to person. emerged in late 2021.

Disease 88

Disease DNA Virus RNA 88

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

Drug Target Review

OCTOBER 2, 2024

Early-phase clinical trials have shown the safety and efficacy of using stem cells for cardiac repair, encouraging further research and development. RNA-based therapies, including mRNA and RNA interference (RNAi), are being explored to modulate gene expression in heart cells.

Therapies 98

Therapies Disease RNA Engineering 98

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 21, 2021

The approval was built on the Phase III ATLAS and FLAIR trials. In the trials, Cabenuva was as effective as a daily oral three-drug regimen. In the trials, Cabenuva was as effective as a daily oral three-drug regimen. In addition to the ATLAS and FLAIR trials, ViiV sponsored the CUSTOMIZE clinical trial.

FDA Approval 52

FDA Approval Treatment FDA Clinical Trials 52

NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

Then came even bigger news a few days later when Pfizer announced interim results from a large phase 2/3 clinical trial. The SARS-CoV-2 virus encodes its own protease to help process a large virally-encoded polyprotein into smaller segments that it needs for its life cycle; a protease inhibitor drug can stop that from happening.

Clinical Trials 52

Clinical Trials Virus Hospitals FDA 52

KIF1A

FEBRUARY 4, 2024

In addition to sequencing patients, the researchers looked for antibodies to the HTLV-1 virus in the patients’ spinal fluid. We each have two DNA copies of the KIF1A gene; each copy is called an allele and makes its own RNA, which is then translated into protein.

RNA 52

RNA DNA Disease Trials 52

The Pharma Data

DECEMBER 16, 2020

The Moderna vaccine is similar to Pfizer and BioNTech’s vaccine in the sense that they both use an approach utilizing messenger RNA (mRNA). The technology leveraged to create the vaccine does not require the actual virus, according to CNN. Both vaccines have shown about 95% efficacy in preventing novel coronavirus infections.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

OCTOBER 19, 2020

With over 300 active clinical trials, Winship researchers are dedicated to taking new cancer treatments from bench to bedside. cancer centers selected as a Lead Academic Participating Site for the NCI’s National Clinical Trials Network (NCTN). Winship is one of 32 U.S. MBA, FACP, Chairman of the Caris Precision Oncology Alliance.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

PerkinElmer

AUGUST 18, 2020

The time sensitivity of virus research, combined with an increasing complexity of bench tasks, can make it helpful for labs to increase automaticity of experiments. For this reason, it might be necessary for research teams to screen many potential leads before they find one or two with strong potential. Sources Zhang et al.

Virus 52

Virus Vaccine RNA DNA 52

Drug Target Review

JULY 5, 2023

In terms of targeted gene insertion, we presented data on a new gene-editing endonuclease called UltraSlice nickase, which is a novel protein-based gene editing system that is very different to CRISPR, as it does not involve a guide RNA.

Therapies 103

Therapies DNA Engineering Virus 103

The Pharma Data

OCTOBER 30, 2020

30, 2020 — Viral load was decreased at day 11 for patients with mild or moderate COVID-19 who received a single intravenous infusion of virus-neutralizing monoclonal antibody versus placebo, according to a study published online Oct. percent of viral RNA at day 11. FRIDAY, Oct. 28 in the New England Journal of Medicine.

RNA 52

RNA Virus Hospitals Trials 52

The Pharma Data

MAY 17, 2021

response in the over-50s, the age group deemed at higher risk for contracting the severe form of the virus. . The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ? The Phase 3 study on the vaccine is expected to start in the coming weeks.

Immune Response 52

Immune Response Vaccine Trials RNA 52

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. Gene Delivery Systems Genetic material, in the form of DNA or RNA, does not easily enter cells without the aid of a delivery system.

Engineering 52

Engineering Clinical Research Research Virus 52

The Pharma Data

NOVEMBER 18, 2020

The California company said that clinical trials showed 100% of patients were able to perform the Lucira test in about two minutes. Lab tests that look for the coronavirus’s genetic material using a technique called polymerase chain reaction (PCR) are still considered the gold standard for detecting the virus.

FDA Approval 52

FDA Approval FDA Vaccine Virus 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. The study is an event-driven trial. Argentina and Brazil.

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

New Drug Approvals

SEPTEMBER 6, 2024

1 , 2 It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants). Toll/IL-1 receptor family members are important regulators of inflammation and host resistance. Nature Immunol., 11:373-384 (2010)).

RNA 62

RNA Clinical Trials DNA Disease 62

Codon

APRIL 2, 2023

Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). By combining this new variant with standard sequencing methods, it’s possible to identify RNA modifications in a really simple way. Nucleic Acids Research. Communications Biology.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

MAY 17, 2021

The adjuvanted vaccine suffered a serious setback in December when a phase 1/2 trial showed the candidate delivered only a weak response in older adults ( DID , Dec. 2 virus and the variant first identified in South Africa. Preliminary results from that trial are expected in the third quarter ( DID , March 15 ). ? 14, 2020 ).

Vaccine 40

Vaccine Immune Response RNA Virus 40

Codon

MAY 30, 2023

The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.

DNA 52

DNA RNA Engineering Vaccine 52

The Pharma Data

NOVEMBER 5, 2020

5 of its ongoing Phase 2 extension study, Study 211, examining vebicorvir (VBR, or ABI-H0731) in patients with hepatitis B virus infection. The company’s other two Phase 2 trials, Study 201 and 202, showed that the addition of VBR to NrtI therapy achieved a quicker, deeper level of viral suppression than with NrtI alone.

Virus 40

Virus Clinical Trials Therapies Pharmacokinetics 40

The Pharma Data

NOVEMBER 17, 2020

After getting the virus under control, California Gov. Until now, Reynolds had ignored infectious disease experts who say masks are one of the most effective tools to control the spread of the virus, the Post reported. That fragment sets off alarms in the immune system and stimulates it to attack if the real virus shows up.

Vaccine 52

Vaccine Virus RNA Hospitals 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

Drug Target Review

SEPTEMBER 25, 2024

8 Preliminary data from the trial have shown good safety and tolerability for TT125-802, with confirmed preliminary target engagement in surrogate tissues such as hair follicles and peripheral blood mononuclear cells. Notably, TT125-802 stabilised disease and prevented further outgrowth of tumours resistant to standard-of-care treatment.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

SEPTEMBER 1, 2020

This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. Roche has an ongoing clinical trial program evaluating the role of Actemra©/RoActemra© (tocilizumab) in COVID-19 pneumonia.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

Codon

APRIL 9, 2023

Small snippets of double-stranded RNA were sprayed onto hot pepper plants to control a pest, called Frankliniella occidentalis. The RNA strands shut down a specific gene in the insects, and killed half after 7 days. RNA may offer a safer form of pest control in the future. The new sequences might help de-extinction efforts.

Therapies 52

Therapies RNA Engineering Vaccine 52

The Pharma Data

SEPTEMBER 3, 2020

First commercial test for fully automated high throughput systems to detect and differentiate SARS-CoV-2, influenza A virus and/or influenza B virus with a single sample. The test has been authorised only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.

FDA 40

FDA Virus Laboratories Clinical Trials 40